NGL FINECHEM
Back to Cashflow Statement
|
NGL FINECHEM Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹30 Cr | ₹37 Cr | ₹-1.08 Cr | ₹-1.08 Cr | ₹-1.08 Cr |
What is the latest Cash Flow from Financing Activities ratio of NGL FINECHEM ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹30 Cr |
| Mar2025 | ₹37 Cr |
| Mar2024 | ₹-1.08 Cr |
| Mar2023 | ₹-1.08 Cr |
| Mar2022 | ₹-1.08 Cr |
How is Cash Flow from Financing Activities of NGL FINECHEM Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹30 Cr | -21.15 | |
| Mar2025 | ₹37 Cr | Positive | |
| Mar2024 | ₹-1.08 Cr | Negative | |
| Mar2023 | ₹-1.08 Cr | Negative | |
| Mar2022 | ₹-1.08 Cr | - | |
Compare Cash Flow from Financing Activities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,764.9 Cr | 6.2% | -3.8% | 91.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹442,437.0 Cr | -0.5% | -3% | 16% | Stock Analytics | |
| DIVIS LABORATORIES | ₹248,054.0 Cr | 1.6% | 9.3% | 54.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,842.0 Cr | 3.5% | 2.3% | 40.6% | Stock Analytics | |
| CIPLA | ₹111,565.0 Cr | 1.6% | -3.2% | -11.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,163.0 Cr | 5.8% | 3.2% | -8.3% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 6.2% |
-3.8% |
91.4% |
| SENSEX | 0.7% |
-3.9% |
-8.9% |
You may also like the below Video Courses